Organization | Genitope Corporation

Genitope Corporation Report issue

For profit Phase 2 Phase 3

Founded: Fremont CA United States (1996)

Status: Defunct (2008)

Organization Overview

First Clinical Trial

1999

NCT00004198

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2007

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 3 Trials (6)

autologous immunoglobulin idiotype-klh conjugate vaccine (3 trials)

cyclophosphamide (cytoxan) (1 trial)

keyhole limpet hemocyanin (2 trials)

prednisone (meticorten) (1 trial)

sargramostim (leukine) (3 trials)

vincristine (oncovin) (1 trial)

Drugs in Phase 2 Trials (2)

idiotype tumor cell vaccine (1 trial)

myvax (1 trial)

Drugs in Other Trials (1)

id-klh vaccine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lymphoma (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 6
# of Trial APIs: 9